Clinical Roundup Protein behind necroptotic cell death could drive new treatment strategies December 12, 2025Vol.51 No.45
Drugs & Targets FDA publishes updated CAR T regulatory framework December 12, 2025Vol.51 No.45By Jacquelyn Cobb
Drugs & Targets Augmentin XR becomes first drug to receive FDA approval through Commissioner’s National Priority Voucher Pilot Program December 12, 2025Vol.51 No.45
Drugs & Targets FDA grants Breakthrough Therapy designation for Tecvayli + Darzalex Faspro as a second line treatment for r/r MM December 12, 2025Vol.51 No.45
Drugs & Targets FDA approves robotic-assisted surgery system for urologic surgical procedures December 12, 2025Vol.51 No.45
Drugs & Targets FDA approves first CAR T-cell therapy for marginal zone lymphoma December 12, 2025Vol.51 No.45
Conversation with The Cancer Letter Anthony Letai pledges to ensure stability for extramural and intramural cancer science December 05, 2025Vol.51 No.44By Paul Goldberg
NCI In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook December 05, 2025Vol.51 No.44By Jacquelyn Cobb
Regulatory News Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulationsBIO calls for the end of “constant turmoil,” urges the administration to “right the ship” December 05, 2025Vol.51 No.44By Paul Goldberg
Cancer Policy Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report December 05, 2025Vol.51 No.44By Sara Willa Ernst
